Formulation, Characterization, and Potential Therapeutic Implications of Encapsulated Recombinant Alpha-Luffin in Niosomes.

Autor:	Joni HA; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran., Esmaeili F; Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran., Landi B; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Bayat E; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Bakhshandeh H; Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran., Talebkhan Y; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Barkhordari F; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Sadeghi S; Department of Nano Biotechnology, New Technology Research Group, Pasteur Institute of Iran, Tehran, Iran., Nematollahi L; Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran., Negahdari B; Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Jazyk:	angličtina
Zdroj:	Current pharmaceutical biotechnology [Curr Pharm Biotechnol] 2024 Aug 23. Date of Electronic Publication: 2024 Aug 23.
DOI:	10.2174/0113892010316435240806053230
Abstrakt:	Objective: The anticancer properties of recombinant α-luffin (LUF) are wellestablished. However, the cytotoxic effects of encapsulating LUF within niosomes on the SKBR3 breast cancer cell line have yet to be explored. Our study aimed to investigate whether this encapsulation strategy could improve cytotoxic effects. Methods: Alpha-luffin was expressed, purified, and refolded. Then, this protein was utilized to craft an optimal formulation, guided by experimental design. In this work, we have explored various physicochemical properties, including particle size, polydispersity index, zeta potential, morphology, entrapment efficiency, drug release and kinetics, storage stability, and FTIR spectroscopy. Additionally, we have assessed the cellular uptake and cytotoxic effect of the optimized niosome formulation on the SKBR3 breast cancer cell line. Results: The optimized niosome exhibited a mean diameter of 315±6.4 nm (DLS). Successful encapsulation of LUF into regularly shaped, spherical niosomes was achieved, with an encapsulation efficiency of 73.45±2.4%. Notably, Niosomal LUF (NLUF) exhibited significantly increased cytotoxicity against SKBR3 cells. Conclusion: These findings suggest that niosomes loaded with LUF hold promise as a potential treatment strategy for breast cancer. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu